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Tolerance Induction by the Blockade of CD40/CD154
Interaction in Pemphigus Vulgaris Mouse Model
Miyo Aoki-Ota1,2, Mari Kinoshita1, Takayuki Ota1, Kazuyuki Tsunoda1,3, Toshiro Iwasaki2, Sigeru Tanaka4,
Shigeo Koyasu5, Takeji Nishikawa1 and Masayuki Amagai1
Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein
3 (Dsg3). We have recently developed an active disease mouse model for PV by adoptive transfer of splenocytes
from Dsg3/ mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the
pathogenic antibody production and development of the disease in PV model mice. When anti-CD154
monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb
almost completely blocked the anti-Dsg3 IgG production and prevented blister formation. The blockade of
CD40/CD154 interaction induced tolerance against Dsg3 as the suppression of antibody production was
observed through day 70, and it was maintained even after challenge by immunization with recombinant mouse
Dsg3 or by adoptive transfer of immunized Dsg3/ splenocytes. Furthermore, the tolerance to Dsg3 was
transferable because cotransfer of splenocytes from anti-CD154 mAb-treated mice and naı¨ve Dsg3/
splenocytes significantly suppressed anti-Dsg3 IgG production in recipient mice. In contrast, when anti-
CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the
production of anti-Dsg3 IgG was observed. These findings indicate that the CD40/CD154 interaction is essential
for the induction of pathogenic anti-Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells
induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.
Journal of Investigative Dermatology (2006) 126, 105–113. doi:10.1038/sj.jid.5700016
INTRODUCTION
Pemphigus vulgaris (PV) is a life-threatening autoimmune
blistering disease of the skin and mucous membranes caused
by autoantibodies against desmoglein 3 (Dsg3) (Amagai,
2003). It is characterized histologically by blister formation
owing to the loss of cell–cell adhesion of keratinocytes and
immunopathologically by the presence of bound and
circulating IgG against the cell surfaces of keratinocytes.
Anti-Dsg3 IgG autoantibodies play a pathogenic role in
blister formation, and the antibody titers of patients often
correlate with the intensity of disease activity (Amagai et al.,
1991, 2000; Ishii et al., 1997; Cheng et al., 2002).
The interaction between antigen-specific T cells and B
cells via their co-stimulatory molecules is required for
efficient antibody production. One of these co-stimulatory
molecules, CD154 (CD40 ligand), is expressed transiently on
activated T cells; it binds to CD40 on antigen-presenting
cells, including B cells. The interaction of CD40 with CD154
is essential for the priming of T cells by dendritic cells and
initiation of the T-cell-dependent humoral immune re-
sponses, leading to proliferation and differentiation of B cells
(Noelle et al., 1992; Foy et al., 1993; Korthauer et al., 1993;
Kawabe et al., 1994; Datta and Kalled, 1997; Mackey et al.,
1998). Thus, the blockade of the CD40/CD154 interaction
has been an attractive immunoregulatory strategy for the
suppression of autoantibody production in autoimmune
diseases. In PV, anti-Dsg3 autoantibodies are of IgG isotypes,
which may be produced after isotype switching; they have
high affinity against Dsg3, possibly as a result of affinity
maturation. In addition, PV sera recognize several distinct
epitopes on the Dsg3 molecule (Amagai et al., 1992;
Sekiguchi et al., 2001), and the presence of anti-Dsg3
autoantibodies is associated with specific HLA class II alleles,
including DRB1*0402, DRB1*1401, and DQB1*0302 in
Caucasians (Sinha et al., 1988; Ahmed et al., 1990, 1991),
and DRB1*14 and DQB1*0503 in Japanese subjects (Niizeki
et al., 1991, 1994; Miyagawa et al., 1997). All of these
features suggest that anti-Dsg3 antibody production is T-cell-
dependent. In addition, a critical role of autoreactive T cells
in the induction and regulation of antibody production has
been suggested by recent studies. The activation of auto-
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reactive B cells was almost completely blocked by the
depletion of CD4þ T cells from the peripheral lymphocyte
pool (Nishifuji et al., 2000), and Dsg3-reactive Th2 cells were
detected in patients with active PV (Veldman et al., 2003).
Recently, we developed a mouse model for active PV
disease by adoptive transfer of Dsg3/ splenocytes to mice
that express Dsg3 (Amagai et al., 2000; Amagai, 2002;
Ohyama et al., 2002; Aoki-Ota et al., 2004). Immunological
tolerance against Dsg3 should not be acquired in Dsg3/
mice because immunomodulating cells are never exposed to
Dsg3 during the development of the immune system. We
adoptively transferred splenocytes from the immunized or
naı¨ve Dsg3/ mice into Rag2/ recipient mice that
expressed Dsg3. Anti-Dsg3 IgG was stably produced in the
Rag2/ recipient mice and bound in vivo to keratinocyte
cell surfaces, and caused suprabasilar acantholysis in the oral
mucosa and esophagus. As a result, the mice showed weight
loss due to the inhibition of food intake. The recipient mice
also developed patchy hair loss or telogen hair loss. The
antibody production was stable and observed over 6 months
after the adoptive transfer. This model provides a valuable
tool for the elucidation of the molecular and cellular events
essential for the production of pathogenic anti-Dsg3 IgG, as
well as for the evaluation of various therapeutic strategies
(Tsunoda et al., 2002, 2003). In this study, we used the mouse
model of PV to examine the importance of the CD40/CD154
interaction for the production of pathogenic anti-Dsg3 IgG
antibodies and to evaluate the efficacy of anti-CD154
monoclonal antibody (mAb) in the prevention and treatment
of PV. Further, we evaluated the long-lasting effect induced
by blockade of CD40/CD154 interaction.
RESULTS
Anti-CD154 mAb prevented production of anti-Dsg3 IgG and
induction of the PV phenotype
To examine the effects of anti-CD154 mAb (MR1) on the
development of PV in the mouse model, Rag2/ recipient
mice (n¼6) were injected intraperitoneally (i.p.) with 500mg
of anti-CD154 mAb (early treatment group) or control
hamster IgG (control group) on days 2, 0, 2, 4, 7, and 14
of the adoptive transfer of immunized Dsg3/ splenocytes.
The mice were monitored for the production of anti-Dsg3
antibody using an ELISA and for the appearance of the PV
phenotype until day 70 (Figures 1 and 2). All of the control
mice had detectable levels of anti-Dsg3 IgG by day 14 after
adoptive transfer, reached a plateau by day 21, and
consistently produced anti-Dsg3 IgG thereafter (Figure 2a).
In contrast, the production of anti-Dsg3 IgG after adoptive
transfer was almost completely inhibited in all of the mice
that received early treatment with anti-CD154 mAb, and the
inhibition continued through day 70 (Figure 2a). The control
mice developed telogen hair loss (Figure 1a, day 33) and
suffered weight loss that was apparent at day 14 (when anti-
Dsg3 IgG production was first detected), reaching a plateau at
days 21–28 (Figure 2b). The controls also showed in vivo
deposition of IgG on keratinocyte cell surfaces in the oral
mucosa (Figure 1c) and suprabasilar acantholysis, a typical
histological finding in PV (Figure 1e). In contrast, the mice
treated early with anti-CD154 mAb did not show any signs of
the PV phenotype. The treated mice did not develop hair loss
(Figure 1a), had no in vivo deposition of IgG on keratinocyte
cell surfaces (Figure 1b), and showed no histological signs of
intraepidermal blister formation (Figure 1d); no weight loss
was observed in the treated mice through day 70 (Figure 2b).
We also examined the ongoing antibody production in the
spleen, lymph nodes, and bone marrow by enzyme-linked
immunospot assay at day 28 (Figure 3a, n¼ 2). In the control
mice, B cells producing anti-Dsg3 IgG were detected
(157.3721.3/105 mononuclear cells in the spleen;
63.1712.9/105 cells in the lymph nodes; 10.075.7/105 cells
in the bone marrow). In contrast, in the mice treated early
with anti-CD154 mAb, no B cells producing anti-Dsg3 IgG
were detected in any of the lymphoid organs. We also
examined the adaptation of transferred cells in the spleen by
flow cytometric analysis (Figure 3b). Similar numbers of
CD19þ B cells (7.6570.84/105 cells in anti-CD154 mAb-
a
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Figure 1. Anti-CD154 mAb prevents the development of the PV phenotype
in mice with experimentally induced PV. The mice that received control
hamster IgG developed telogen hair loss and weight loss (a; two mice on the
right, day 33), and showed in vivo IgG deposition on keratinocyte cell
surfaces (c; hard palate) and suprabasilar acantholysis on histologic
examination (e; hard palate). In contrast, the mice treated with anti-CD154
mAb developed no apparent telogen hair loss or weight loss (a; two mice on
left, day 33), and had no deposition of IgG in the stratified squamous epithelia
(b; hard palate) and no intraepithelial blister formation (d; hard palate).
Bars¼ 50 mm.
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treated mice; 6.3770.47/105 cells in the control mice;
P40.05) and CD4þ T cells (3.3470.27/105 cells in anti-
CD154 mAb-treated mice; 5.3070.52/105 cells in the
control mice; P40.05) were detected in both the groups
receiving anti-CD154 mAb and control IgG (n¼ 4).
These findings indicated that, when administered close to
the time of the adoptive transfer of Dsg3/ splenocytes, anti-
CD154 mAb almost completely blocks the production of
anti-Dsg3 IgG, as well as the development of the PV
phenotype, without affecting the general composition of the
lymphocyte population.
Early treatment with anti-CD154 mAb induced tolerance to
Dsg3
The suppression of the production of anti-Dsg3 antibodies by
early treatment with anti-CD154 mAb was observed even
after the discontinuation of treatment and lasted at least until
day 70, when the experiment was terminated (Figure 2a). This
finding indicated that the effect of anti-CD154 mAb was not
transient; unresponsiveness to Dsg3 persisted despite the
presence of Dsg3 in the stratified squamous epithelia of the
recipient mice.
We further challenged this unresponsiveness to Dsg3 by
active immunization. The mice treated with anti-CD154 mAb
were immunized with recombinant mouse Dsg3 (mDsg3) in
complete Freund’s adjuvant on day 42 and were given a
second dose in incomplete Freund’s adjuvant on day 63
(n¼5). The production of anti-Dsg3 IgG was determined by
incubating the serum samples with live keratinocytes,
followed by a fluorescent secondary antibody, to detect
binding of anti-Dsg3 IgG to native Dsg3 (Figure 4). Even after
active immunization, no IgG that reacted with native Dsg3
was detected on days 56 and 70. In addition, the treated mice
did not develop any gross or microscopic signs of the PV
phenotype after active immunization. However, the mice
retained antibody responses against other irrelevant antigens
because Dsg3 ELISA became positive after immunization
with Dsg3 probably due to antibodies raised against minor
contaminants in purified recombinant Dsg3 preparation (data
not shown). To exclude the possibility that this prolonged
unresponsiveness only occurred in the absence of newly
developed B cells, we performed bone marrow transfer from
Dsg3/ mice on day 23 to the mice treated with anti-CD154
mAb and immunized them with mDsg3 in complete Freund’s
adjuvant on day 37. Thereafter, the mice were given a second
dose in incomplete Freund’s adjuvant on day 51 (n¼ 5).
Again, no IgG reacting with Dsg3 was detected on day 49 or
70 and no apparent PV phenotype was observed in these
mice (data not shown).
Transferable immune-regulatory cells were induced by early
treatment with anti-CD154 mAb
We further investigated the mechanism involved in the
tolerance seen in the mice treated with anti-CD154 mAb. We
especially attempted to determine whether the tolerance was
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Figure 2. Anti-CD154 mAb prevents the production of anti-Dsg3 IgG and
loss of weight. (a) The titers of anti-Dsg3 IgG were measured by ELISA against
mDsg3 at various time points after the adoptive transfer (solid squares,
anti-CD154 mAb, n¼6; open circles, control IgG, n¼ 6). The production
of anti-Dsg3 IgG was almost completely inhibited in all of the mice that
received early treatment with anti-CD154 mAb. (b) Changes in body
weight were monitored throughout the course of the experiment. The
mice that received anti-CD154 mAb did not lose weight, whereas the
mice that received control IgG did.
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Figure 3. Suppression of anti-Dsg3 IgG-producing B cells by anti-CD154
mAb does not affect the general composition of the lymphocyte population.
(a) Anti-Dsg3 IgG-producing B cells in the spleen, lymph nodes, and bone
marrow on day 28 were detected using an enzyme-linked immunospot assay
against mDsg3 in mice that received anti-CD154 mAb (solid bars, n¼2) or
control IgG (open bars, n¼ 2). No anti-Dsg3 IgG-producing B cells were
detected in the mice that received anti-CD154 mAb. (b) Flow cytometric
analysis to detect CD4þ T cells and CD19þ B cells among the splenocytes
from mice treated with anti-CD154 mAb or control IgG. There was no
substantial difference in the composition of the splenocytes between the two
groups.
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induced by apoptosis or anergy of effector cells or immune-
regulatory cells. We challenged the unresponsive to Dsg3 by
retransfer of immunized Dsg3/ splenocytes. After the PV
model mice treated with anti-CD154 mAb were confirmed to
have no detectable anti-Dsg3 IgG by ELISA at day 49, the
mice were retransferred with immunized Dsg3/ spleno-
cytes at day 53. While Rag2/ recipient mice receiving
immunized Dsg3/ splenocytes produced anti-Dsg3 IgG
(Figure 5, open circle, n¼4) and developed the typical PV
phenotype including weight loss and telogen hair loss, the PV
model mice that had been treated with anti-CD154 mAb only
barely produced anti-Dsg3 IgG after the second transfer
(Figure 5, solid squares, n¼4) and did not develop any
apparent PV phenotype at all.
To further determine whether the tolerance to Dsg3 is
transferable, we isolated splenocyte from the PV model mice
that had been treated with anti-CD154 mAb and adoptively
transferred 3107 of these cells mixed with 3107 naı¨ve
splenocytes from Dsg3/ mice. When 3107 naı¨ve Dsg3/
splenocytes were transferred alone, the mice started to
produce anti-Dsg3 IgG at day 20, and reached a plateau
around day 40, and consistently produced anti-Dsg3 IgG
thereafter (Figure 6a, open circle, n¼ 1) (Aoki-Ota et al.,
2004). In contrast, when the splenocytes from the PV model
mice treated with anti-CD154 mAb were transferred together
with naı¨ve Dsg3/ splenocytes, the mice did not produce any
detectable anti-Dsg3 IgG, and the inhibition of the antibody
production continued, as long as we observed, through day 83
(Figure 6a, solid squares, n¼ 3). The control mice suffered
weight loss, which was apparent at day 20 and progressively
seen thereafter, and developed telogen hair loss (Figure 6b
(open circle) and Figure 6d). In contrast, the mice receiving
splenocytes from anti-CD154 mAb-treated mice did not show
any signs of weight loss or telogen hair loss (Figure 6b (solid
squares) and Figure 6c).
These findings indicated that early treatment with anti-
CD154 mAb, close to the time of adoptive transfer of
splenocytes, induced tolerance to Dsg3 by induction of
transferable immune-regulatory cells.
Blockade of CD40/CD154 interaction did not show significant
therapeutic effects once the production of anti-Dsg3 IgG was
established
We next examined the therapeutic effects of anti-CD154
mAb in mice after the production of anti-Dsg3 IgG was
established and the mice had developed the active PV
phenotype. After the adoptive transfer of immunized Dsg3/
splenocytes, we waited 28 days to allow the mice to develop
the PV phenotype and then injected 1.0 mg of anti-CD154
mAb i.p. twice per week for 6 weeks (delayed treatment
group). We used normal hamster IgG as a control. We
compared the anti-Dsg3 IgG titers and PV scores over time,
setting the day that treatment was initiated as day 0 (Figure 7).
The data for each group were analyzed as the ratio of the
mean titers at each time point to the mean titers on day 0.
Surprisingly, there was no significant difference in the anti-
Dsg3 titers in mice that received delayed treatment with anti-
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Figure 4. Immunization with mDsg3 failed to induce anti-Dsg3 IgG that can bind to native Dsg3 in mice that had received anti-CD154 mAb. The production
of anti-Dsg3 IgG was evaluated by incubation of serum samples with live keratinocytes, followed by staining with FITC-conjugated goat anti-mouse IgG
antibody. Mice that received control IgG produced anti-Dsg3 IgG by day 14. In contrast, mice given anti-CD154 mAb did not produce any detectable anti-Dsg3
IgG by day 28. This unresponsiveness was maintained at least through day 70, even after active immunization with mDsg3 on days 42 and 63; ND¼not
determined.
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Figure 5. The unresponsiveness to Dsg3 is maintained even after the second
transfer of immunized Dsg3/ splenocytes in PV model mice treated with
anti-CD154 mAb. The PV model mice that had been treated with
anti-CD154 mAb were challenged by the second adoptive transfer of
splenocytes from immunized Dsg3/ mice (solid squares, n¼ 4), but the
production of anti-Dsg3 IgG was only barely seen (solid squares; n¼ 4).
In contrast, Rag2/ recipient mice receiving the same batch of immunized
Dsg3/ splenocytes produced anti-Dsg3 IgG and developed the PV
phenotype (open circles; n¼ 4). Days are indicated after the second
transfer and days from the first transfer are indicated within parentheses.
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CD154 mAb and those treated with control hamster IgG
(P¼0.94 at day 42; Figure 7a). Although the PV scores were
slightly lower in the delayed treatment group than in the
control group at day 42, the difference was not statistically
significant (P¼ 0.52), and the PV scores were essentially the
same at the other time points (Figure 7b).
We also studied the effects of anti-CD154 mAb in a mouse
model of PV produced by adoptive transfer of naı¨ve Dsg3/
splenocytes (Aoki-Ota et al., 2004). Mice that receive naı¨ve
Dsg3/ splenocytes do not develop the PV phenotype as
quickly as those that receive immunized Dsg3/ spleno-
cytes; thus, the delayed treatment with anti-CD154 antibody
was initiated 42 days after the adoptive transfer and
continued as described above. In mice receiving anti-
CD154 mAb, the anti-Dsg3 IgG titers decreased continuously
and were lower than those of the control mice throughout the
course of this study; however, these differences did not reach
statistical significance (P¼0.28 at day 56; Figure 7c). The PV
score also decreased in mice treated with anti-CD154 mAb,
with gradual improvement during the course of the study.
However, again there was no statistically significant differ-
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Figure 6. Tolerance to Dsg3 is transferable. (a) Cotransfer of the splenocytes
from PV model mice treated with anti-CD154 mAb suppressed the production
of anti-Dsg3 IgG by naı¨ve Dsg3/ splenocytes in Rag2/ recipient mice
(solid squares, cotransfer of anti-CD154 mAb-treated splenocytes and naı¨ve
Dsg3/ splenocytes, n¼ 3; open circles, transfer of naı¨ve Dsg3/
splenocytes only, n¼ 1). (b) Changes in body weight were monitored
throughout the course of the experiment. The mice that received anti-CD154
mAb-treated splenocytes and naı¨ve Dsg3/ splenocytes did not lose weight,
whereas the mice that received only naı¨ve Dsg3/ splenocytes did. Gross
appearance of mice that received only naı¨ve Dsg3/ splenocytes (c) at day
70. (d) and of mice that received anti-CD154 mAb-treated splenocytes and
naı¨ve Dsg3/ splenocytes.
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Figure 7. Effects of delayed treatment with anti-CD154 mAb on PV model
mice after development of the PV phenotype. The effects were evaluated on
PV model mice induced by transfer of immunized Dsg3/ splenocytes (a, b)
and naı¨ve Dsg3/ splenocytes (c, d). The titers of anti-Dsg3 IgG measured by
ELISA against mDsg3 (a, c) and the PV scores (b, d) were monitored at various
time points during the course of the experiment. Anti-CD154 mAb failed to
show any significant therapeutic effects after the mice had developed
symptoms of active PV disease.
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ence between the two groups regarding the PV score
(P¼0.21 at day 56; Figure 7d).
These findings indicated that delayed administration of
anti-CD154 mAb failed to decrease significantly the produc-
tion of anti-Dsg3 IgG or to ameliorate the symptoms of PV
after the PV phenotype was established in mice following
adoptive transfer of Dsg3/ splenocytes.
DISCUSSION
In this study, we demonstrated that the blockade of the CD40/
CD154 interaction by treatment with anti-CD154 mAb
inhibited the production of anti-Dsg3 IgG as well as the
development of the PV phenotype in a mouse model of PV
when the treatment was given close to the time of adoptive
transfer. The inhibition of the development of the PV
phenotype by early treatment with anti-CD154 mAb was
unequivocal. The inhibition of pathogenic antibody produc-
tion was demonstrated by an ELISA to detect circulating anti-
Dsg3 IgG and by an enzyme-linked immunospot assay
against mDsg3 to detect ongoing production of anti-Dsg3
IgG by B cells in the spleen, lymph nodes, and bone marrow.
Preventive effects of the blockade of the CD40/CD154
interaction have been shown in other autoimmune models
such as autoimmune thyroiditis (Peterson and Braley-Mullen,
1999), collagen-induced arthritis (Durie et al., 1993),
experimental diabetes (Moore et al., 2002), and experimental
murine systemic lupus erythematosus (Early et al., 1996).
These findings indicate that the CD40/CD154 interaction is
essential for the production of pathogenic autoantibodies;
blockade of this interaction efficiently prevented the devel-
opment of these diseases.
It has also been demonstrated that unresponsiveness or
tolerance against Dsg3 can be induced by preventive
blockade of the CD40/CD154 interaction. The inhibition of
anti-Dsg3 IgG production persisted throughout the 70-day
course of the study. Active immunization with mDsg3 in
adjuvant did not overcome the tolerance to Dsg3; mice that
had received early treatment with anti-CD154 mAb did not
produce anti-Dsg3 IgG that could bind to native Dsg3 even
after two injections of the immunogen. This tolerance is
currently thought to be induced by apoptosis or anergy of
antigen-specific T cells or immune-regulatory cells. In the
non-obese diabetic mouse model, co-transfer of splenocytes
from mice that had been treated with anti-CD154 mAb and
splenocytes from mice with induced diabetes did not inhibit
the transfer of the disease (Balasa et al., 1997). In a
myasthenia gravis model, adoptive transfer of splenocytes
from anti-CD154 mAb-treated rats into naı¨ve rats did not
protect the recipients from subsequent induction of the
disease (Im et al., 2001). These results suggest that the
administration of anti-CD154 mAb induced anergy or
apoptosis of self-reacting T cells. On the other hand, in the
RIP-LCMV mouse model of virus-induced type I diabetes,
anti-CD154 mAb-induced protection from the disease could
be transferred by the transfer of a regulatory cell population
sharing phenotypic and functional properties of both natural
killer cells and dendritic cells. Furthermore, the protection of
prediabetic recipients was autoantigen-specific and did not
result in generalized immunosuppression (Homann et al.,
2002). In the cardiac transplant model, recipients treated with
anti-CD154 mAb and donor-specific transfusion had perma-
nent allograft survival and accepted second donor-strain
cardiac allografts probably by induction of CD4þCD25þ
regulatory T cells because depletion of CD25þ cells led to
allograft rejection (Lee et al., 2005).
In PV model mice, the tolerance persisted even after the
anti-CD154 mAb-treated mice were challenged by the
second transfer with Dsg3-primed splenocytes. Furthermore,
the tolerance to Dsg3 was transferable by the transfer of
splenocytes from anti-CD154 mAb-treated mice. These
findings suggested that anti-CD154 mAb induced tolerance
to Dsg3 by induction of immune-regulatory cells. We were
unable to further characterize the profiles of the immune-
regulatory cells because of the low recovery of splenocytes
from the PV model mice. Although the mechanism for the
unresponsiveness induced by anti-CD154 mAb in PV mouse
model needs further investigation, antigen-specific immune-
regulatory cells induced by anti-CD154 mAb treatment could
represent a potent therapeutic option for pemphigus.
In this study, we also examined the therapeutic effects of
the blockade of CD40/CD154 interaction after PV model
mice stably produced anti-Dsg3 IgG and developed the PV
phenotype. The therapeutic effects were not as dramatic as
the complete prevention of disease observed in mice that
received early treatment. Similar less-potent effects of anti-
CD154 mAb in treatment than in prevention have been
observed in other models of autoimmune disease (Balasa
et al., 1997; Kalled et al., 1998; Kyburz et al., 2000; Quezada
et al., 2003). These observations suggest that the CD40/
CD154 pathway might not be required for the maintenance
phase after the establishment of antibody production to the
same degree as it is during the priming or the induction
phase, and, further, that B cells in the late stage of
autoimmune diseases might not require the co-stimulatory
signal and might function in a T-independent manner
(Fagarasan and Honjo, 2000; Shinozaki et al., 2001). On
the other hand, it was recently demonstrated that plasma cells
live longer in the bone marrow than was previously thought
and these long-lived plasma cells play a major role in the
long-term maintenance of antibody production (Manz et al.,
1998; Slifka and Ahmed, 1998). Clarification of the mechan-
ism underlying the rather disappointing therapeutic effects of
anti-CD154 treatment will open new paths for the develop-
ment of novel approaches to arrest unwanted ongoing
autoimmune reactions.
In summary, we demonstrated that the blockade of the
CD40/CD154 interaction by anti-CD154 mAb showed
significant preventive effects on the production of pathogenic
anti-Dsg3 IgG antibodies, as well as on the development of
the disease phenotype in a mouse model of PV. After stable
production of pathogenic antibodies was established, anti-
CD154 treatment had only marginal effects. The early
blockade of CD40/CD154 interaction might induce transfer-
able immune-regulatory cells that could suppress the
production of pathogenic anti-Dsg3 IgG antibodies. Our
findings from the PV mouse model provide important
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information not only for understanding the immunological
mechanisms of long-term antibody production in pemphigus
but also for the development of novel therapeutic strategies
and the design of human clinical trials for treatments of
autoantibody-mediated autoimmune diseases.
MATERIALS AND METHODS
Antibodies
Hamster anti-murine CD40 ligand (CD154) mAb, designated MR1,
was prepared according to the protocol described in the original
report (Noelle et al., 1992). Briefly, hybridoma cells producing MR1
were cultured in Hybridoma SFM medium (Invitrogen, San Diego,
CA) and the supernatant was purified by Protein A affinity
chromatography to obtain MR1. Purified normal hamster IgG was
used as a control (Cappel Product, Aurora, OH).
Adoptive transfer of Dsg3/ splenocytes
Dsg3/ mice were obtained by mating male and female Dsg3/
mice (Amagai et al., 2000; Tsunoda et al., 2002). These mice have a
mixed genetic background of 129/Sv (H-2b) and C57BL/6J (H-2b).
Splenocytes were prepared from either naı¨ve Dsg3/ mice or from
Dsg3/ mice immunized with recombinant mDsg3 protein (extra-
cellular domains). For the immunizations, 6- to 8-week-old Dsg3/
mice were primed subcutaneously with 10 mg of purified mDsg3 in
complete Freund’s adjuvant, then twice with mDsg3 in incomplete
Freund’s adjuvant, and finally boosted twice at 2-week intervals with
i.p. mDsg3 with no adjuvant. For the adoptive transfer, 5 107
splenocytes from naı¨ve Dsg3/ mice or 2 107 splenocytes from
immunized Dsg3/ mice were injected into the tail veins of C57BL/
6 Rag2/ mice. All mouse studies were approved by the animal
ethics review board of Keio University.
Administration of anti-CD154 mAb to pemphigus model mice
To examine the effects of anti-CD154 mAb in the prevention of the
development of PV, each Rag2/ recipient mouse was given 500mg
of anti-CD154 mAb (early treatment group) or hamster control IgG
(control group) i.p. on days 2, 0, 2, 4, 7, and 14 of the adoptive
transfer of immunized Dsg3/ splenocytes. The mice were
monitored for the production of anti-Dsg3 antibody using an ELISA
and for weight changes, as representative markers of the PV
phenotype. Mice with experimentally induced PV show weight loss
owing to the development of oral erosions that inhibit food intake
(Amagai et al., 2000; Ohyama et al., 2002). The in vivo production
of anti-Dsg3 IgG was also determined using an enzyme-linked
immunospot assay on day 28.
To examine the effects of anti-CD154 mAb as a treatment of
established PV, we used recipient mice that had received adoptive
transfer of immunized or naı¨ve Dsg3/ splenocytes and were stably
producing anti-Dsg3 IgG accompanied by the conspicuous develop-
ment of the PV phenotype. The mice were injected i.p. with 1.0 mg of
anti-CD154 mAb or control hamster IgG twice a week for a total of
12 injections, and the anti-Dsg3 IgG titers and PV scores were
evaluated every 2 weeks. The comparisons of the antibody titers and
PV scores were performed using the Wilcoxon two-sample test.
Assays for tolerance induction against Dsg3
To examine the induction of tolerance to Dsg3 in mice treated with
anti-CD154 mAb, the mice were challenged by immunization with
10 mg/mouse of mDsg3 in complete Freund’s adjuvant on day 37 and
in incomplete Freund’s adjuvant on day 51. In some experiments,
1 107 mononuclear cells from the bone marrow of naı¨ve Dsg3/
mice were transferred on day 23 to provide newly developed B cells
from bone marrow precursors. The production of anti-Dsg3 IgG at
days 49 and 70 was determined by incubating the serum samples
with live keratinocytes and staining, as described below. The ELISA
against mDsg3 is not suitable for detection of anti-Dsg3 IgG after
immunization because antibodies raised against minor contaminants
of the mDsg3 preparation used for immunization or tags on the
recombinant mDsg3 can result in false-positive reactions (Amagai
et al., 2000).
To determine whether the tolerance induced by blockade of
CD40/CD154 interaction was due to the induction of immune-
regulatory cells or the elimination or inactivation of self-reacting
lymphocytes, the mice that were given anti-CD154 mAb were
challenged by retransfer of immunized Dsg3/ splenocytes. In this
set of the experiments, Rag2/ recipient mice were adoptively
transferred with 2 107 splenocytes from immunized Dsg3/ mice
and 2 mg/mouse of anti-CD154 mAb was administered i.p. at days 1
and 4. After the prevention of anti-Dsg3 IgG production was
confirmed by ELISA at day 49, the mice were challenged by a second
transfer with 2 107 splenocytes from immunized Dsg3/ mice at
day 52 and the production of anti-Dsg3 IgG was examined. To
provide a positive control for the adoptive transfer, 2 107
splenocytes from the same immunized Dsg3/ mice were
transferred to Rag2/ mice.
To further determine whether tolerance against Dsg3 induced by
anti-CD154 mAb was transferable, the splenocytes from the mice
that were given anti-CD154 mAb were retransferred with naı¨ve
splenocytes from Dsg3/ mice. In this set of experiments, Rag2/
recipient mice were adoptively transferred with 2 107 cells from
immunized Dsg3/ mice and 2 mg/mouse of anti-CD154 mAb was
administered i.p. at days 1 and 4. After the inhibition of the anti-
Dsg3 IgG production in the first recipient mice was confirmed at day
14, 3 107 splenocytes from the anti-CD154 mAb-treated mice
were cotransferred with 3 107 cells from naı¨ve Dsg3/ mice to
second Rag2/ recipient mice. Anti-Dsg3 IgG production and
development of PV phenotype were monitored to evaluate the
suppressive effect by anti-CD154-treated splenocytes as long as day
83.
ELISA
Circulating anti-Dsg3 IgG was measured by ELISA using recombi-
nant mDsg3 as the coating antigen, as described previously (Amagai
et al., 2000). Each sample was diluted 100-fold and/or 5000-fold and
run in duplicate. A standard serum obtained from a Dsg3/ mouse
immunized with mDsg3 was used as a positive control, and serum
from a non-immunized mouse was used as a negative control. The
ELISA scores were calculated as index values using the following
formula:
index value
¼ OD450 of sampleOD450 of negative control
OD450 of positive controlOD450 of negative control100:
When the OD exceeded 1.2, the serum sample was further diluted,
and the index value was multiplied by the dilution factor.
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Enzyme-linked immunospot assay
PVDF-bottomed, 96-well Amicon multititer plates (Millipore
Corp., Beverly, MA) were coated with 30 mg/ml of mouse recom-
binant Dsg3 (Nishifuji et al., 2000). Mononuclear cells prepared
from the spleen, bone marrow, and lymph nodes were incubated
on the plates at 371C in a CO2 incubator for 4 hours. The IgG
bound to the membrane was revealed as spots with alkaline
phosphatase-conjugated anti-mouse IgG antibodies (Zymed Labora-
tories Inc., South San Francisco, CA). The number of spots
was counted under a dissecting microscope, and the frequency of
anti-Dsg3-producing B cells was defined as the number of spots per
105 mononuclear cells. All experiments were carried out in
triplicate.
Flow cytometric analysis
Adaptation of the transferred cells in the spleen of the recipient was
confirmed on day 28 by flow cytometric analysis using FITC-
conjugated anti-CD4 (GK1.5-FITC) and phycoerythrin-conjugated
anti-CD19 (1D3-phycoerythrin) (PharMingen, San Diego, CA).
Harvested splenocytes (1 106) were stained with the antibodies
in phosphate-buffered saline containing 2% fetal calf serum and
were subjected to analysis on a FACScan using the CELLQuest
program (Becton Dickinson, San Jose, CA).
Live keratinocyte staining
A mouse keratinocyte cell line, PAM212, was incubated with
mouse serum samples, diluted 40-fold with DMEM, at 371C in a
CO2 incubator for 30 minutes. After washing with phosphate-
buffered saline, the cells were fixed with 100% methanol at
201C for 20 minutes and then incubated with FITC-conjugated
goat anti-mouse antibodies (DAKO A/S, Glostrup, Denmark) at
room temperature for 30 minutes. The specimens were examined
under an Eclipse E800 fluorescent microscope (Nikon Corp., Tokyo,
Japan).
PV score
To evaluate the disease activity in the PV model mice, we intro-
duced the PV score based on counting the affected sites, as
described previously (Aoki-Ota et al., 2004). In brief, the presence
of erosive lesions in any separated area was counted as a score
of 1. The appearance of elongated incisor or canine teeth owing to
a lack of solid food intake was counted as a score of 1. The
development of hair loss in any separated area was counted as
a score of 0.5 or 1. The total possible scores for erosive lesions,
elongation of the teeth, and hair loss were 11, 1, and 3, respectively.
The PV score was determined every 2 weeks after the adoptive
transfer.
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